Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic significance of peripheral myeloid-derived suppressor cells in advanced breast cancer.

Breast cancer (Tokyo, Japan)·2026
Same author

Gastric volvulus complicated with a wandering spleen.

Internal medicine (Tokyo, Japan)·2026
Same author

Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study.

International journal of clinical oncology·2026
Same author

Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis.

Cancer science·2026
Same author

KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025
Same author

Targeting Interleukin-6 as a Novel Strategy to Overcome Eribulin Resistance in Breast Cancer.

Cancer medicine·2025

Related Experiment Video

Updated: Jun 28, 2026

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Basal-like subtype and BRCA1 dysfunction in breast cancers.

Yasuo Miyoshi1, Keiko Murase, Koushi Oh

  • 1Department of Breast and Endocrine Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan. ymiyoshi@hyo-med.ac.jp

International Journal of Clinical Oncology
|October 24, 2008
PubMed
Summary

Basal-like breast cancers often lose BRCA1, sharing traits with BRCA1-mutated tumors. Understanding these similarities guides new therapeutic strategies for this aggressive cancer.

More Related Videos

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland
06:29

Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland

Published on: June 7, 2019

Related Experiment Videos

Last Updated: Jun 28, 2026

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
08:53

Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1

Published on: February 17, 2011

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland
06:29

Modeling Breast Cancer via an Intraductal Injection of Cre-expressing Adenovirus into the Mouse Mammary Gland

Published on: June 7, 2019

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Basal-like breast cancers (BLBC) exhibit a distinct molecular profile, frequently characterized by BRCA1 loss.
  • These cancers are triple-negative (estrogen receptor-, progesterone receptor-, and HER2-negative), high-grade, and associated with poor prognosis.
  • Shared genetic alterations, including p53 mutations and EGFR overexpression, link BLBC to BRCA1-mutated cancers.

Purpose of the Study:

  • To elucidate the common pathogenic pathways in BRCA1-mutated and basal-like breast cancers.
  • To explore potential therapeutic strategies based on shared molecular characteristics.
  • To evaluate the potential efficacy of different chemotherapies in basal-like breast cancer.

Main Methods:

  • Comparative analysis of molecular expression profiles in basal-like and BRCA1-mutated breast cancers.
  • Review of existing clinical data on chemotherapy response in basal-like breast cancer.
  • In vitro studies investigating sensitivity to DNA-damaging agents.

Main Results:

  • Disruption of BRCA1 is a key event in basal-like breast cancer pathogenesis, similar to BRCA1-mutated cancers.
  • Anthracycline-based chemotherapy may be effective in a subset of basal-like cancers, potentially due to BRCA1 disruption and topoisomerase II-alpha.
  • Basal-like cancers with disrupted BRCA1 may respond to DNA-damaging agents like platinum compounds and alkylating agents.

Conclusions:

  • Understanding shared genetic and epigenetic pathways is crucial for developing targeted therapies for basal-like breast cancer.
  • Anthracycline chemotherapy shows promise for a subset of patients, but prognosis is poor for non-responders.
  • Future therapies should focus on molecular targets within the pathogenic pathways of basal-like breast cancer, especially for chemotherapy-resistant cases.